Table 3 Subgroup analyses.
Subgroup | Number | AF | |||
|---|---|---|---|---|---|
Event | IR per 1000 PY | Adjusted HR* (95% CI) | P- for-interaction | ||
Total population | |||||
Menopause | |||||
No | No SLD | 4182 | 0.65 | 1 (reference) | < 0.0001 |
MASLD | 1008 | 1.08 | 1.47 (1.37–1.58) | ||
MASLD with other combined etiology | 76 | 1.61 | 2.03 (1.62–2.55) | ||
MetALD | 63 | 1.50 | 2.12 (1.65–2.72) | ||
ALD | 14 | 1.67 | 2.26 (1.34–3.83) | ||
Yes | No SLD | 25,337 | 3.43 | 1 (reference) | |
MASLD | 15,085 | 5.00 | 1.28 (1.26–1.31) | ||
MASLD with other combined etiology | 1106 | 5.44 | 1.42 (1.33–1.50) | ||
MetALD | 157 | 4.02 | 1.56 (1.34–1.83) | ||
ALD | 33 | 4.44 | 1.66 (1.18–2.33) | ||
Premenopausal | |||||
Chronic Kidney disease | |||||
No | No SLD | 3967 | 0.64 | 1 (reference) | 0.3994 |
MASLD | 927 | 1.05 | 1.43 (1.33–1.53) | ||
MASLD with other combined etiology | 73 | 1.65 | 2.05 (1.63–2.59) | ||
MetALD | 58 | 1.45 | 2.01 (1.55–2.61) | ||
ALD | 14 | 1.77 | 2.33 (1.37–3.94) | ||
Yes | No SLD | 215 | 0.83 | 1 (reference) | |
MASLD | 81 | 1.58 | 1.45 (1.12–1.88) | ||
MASLD with other combined etiology | 3 | 1.00 | 0.71 (0.22–2.23) | ||
MetALD | 5 | 2.64 | 3.03 (1.25–7.38) | ||
ALD | 0 | 0.00 | . | ||
Heart failure | |||||
No | No SLD | 4176 | 0.64 | 1 (reference) | 0.9768 |
MASLD | 1008 | 1.08 | 1.43 (1.34–1.54) | ||
MASLD with other combined etiology | 76 | 1.61 | 1.94 (1.54–2.44) | ||
MetALD | 63 | 1.50 | 2.07 (1.61–2.66) | ||
ALD | 14 | 1.67 | 2.16 (1.28–3.67) | ||
Yes | No SLD | 6 | 17.39 | 1 (reference) | |
MASLD | 0 | 0.00 | . | ||
MASLD with other combined etiology | 0 | 0.00 | . | ||
MetALD | . | . | . | ||
ALD | . | . | . | ||
Prior myocardial infarction | |||||
No | No SLD | 4173 | 0.64 | 1 (reference) | 0.9978 |
MASLD | 1003 | 1.08 | 1.43 (1.33–1.53) | ||
MASLD with other combined etiology | 74 | 1.58 | 1.90 (1.51–2.40) | ||
MetALD | 63 | 1.50 | 2.07 (1.61–2.67) | ||
ALD | 14 | 1.68 | 2.17 (1.28–3.68) | ||
Yes | No SLD | 9 | 1.77 | 1 (reference) | |
MASLD | 5 | 3.95 | 1.61 (0.54–4.83) | ||
MASLD with other combined etiology | 2 | 7.57 | 2.45 (0.51–11.70) | ||
MetALD | 0 | 0.00 | . | ||
ALD | 0 | 0.00 | . | ||
Prior ischemic stroke | |||||
No | No SLD | 4167 | 0.64 | 1 (reference) | 0.9445 |
MASLD | 1003 | 1.08 | 1.43 (1.34–1.54) | ||
MASLD with other combined etiology | 76 | 1.62 | 1.96 (1.56–2.46) | ||
MetALD | 63 | 1.50 | 2.07 (1.61–2.67) | ||
ALD | 14 | 1.68 | 2.17 (1.28–3.68) | ||
Yes | No SLD | 15 | 2.71 | 1 (reference) | |
MASLD | 5 | 2.95 | 0.92 (0.33–2.55) | ||
MASLD with other combined etiology | 0 | 0.00 | . | ||
MetALD | 0 | 0.00 | . | ||
ALD | 0 | 0.00 | . | ||
Postmenopausal | |||||
Chronic Kidney disease | |||||
No | No SLD | 20,788 | 3.14 | 1 (reference) | 0.548 |
MASLD | 11,562 | 4.50 | 1.29 (1.26–1.32) | ||
MASLD with other combined etiology | 858 | 5.02 | 1.46 (1.36–1.56) | ||
MetALD | 138 | 3.83 | 1.59 (1.34–1.88) | ||
ALD | 30 | 4.39 | 1.74 (1.21–2.49) | ||
Yes | No SLD | 4549 | 5.93 | 1 (reference) | |
MASLD | 3523 | 7.87 | 1.27 (1.22–1.33) | ||
MASLD with other combined etiology | 248 | 7.70 | 1.30 (1.14–1.48) | ||
MetALD | 19 | 6.35 | 1.41 (0.90–2.21) | ||
ALD | 3 | 5.07 | 1.19 (0.38–3.69) | ||
Heart failure | |||||
No | No SLD | 25,228 | 3.42 | 1 (reference) | 0.6506 |
MASLD | 14,986 | 4.98 | 1.29 (1.26–1.31) | ||
MASLD with other combined etiology | 1092 | 5.40 | 1.42 (1.34–1.51) | ||
MetALD | 156 | 4.00 | 1.56 (1.33–1.83) | ||
ALD | 33 | 4.45 | 1.67 (1.18–2.35) | ||
Yes | No SLD | 109 | 16.79 | 1 (reference) | |
MASLD | 99 | 23.73 | 1.47 (1.11–1.92) | ||
MASLD with other combined etiology | 14 | 17.53 | 1.23 (0.70–2.15) | ||
MetALD | 1 | 49.14 | 4.44 (0.65–30.11) | ||
ALD | 0 | 0.00 | . | ||
Prior myocardial infarction | |||||
No | No SLD | 25,133 | 3.42 | 1 (reference) | 0.9742 |
MASLD | 14,926 | 4.98 | 1.29 (1.26–1.31) | ||
MASLD with other combined etiology | 1080 | 5.37 | 1.41 (1.33–1.50) | ||
MetALD | 157 | 4.03 | 1.57 (1.34–1.84) | ||
ALD | 33 | 4.45 | 1.67 (1.18–2.35) | ||
Yes | No SLD | 204 | 7.71 | 1 (reference) | |
MASLD | 159 | 9.65 | 1.26 (1.02–1.55) | ||
MASLD with other combined etiology | 26 | 11.59 | 1.60 (1.06–2.41) | ||
MetALD | 0 | 0.00 | . | ||
ALD | 0 | 0.00 | . | ||
Prior ischemic stroke | |||||
No | No SLD | 24,944 | 3.40 | 1 (reference) | 0.3383 |
MASLD | 14,804 | 4.96 | 1.29 (1.26–1.31) | ||
MASLD with other combined etiology | 1071 | 5.35 | 1.41 (1.33–1.50) | ||
MetALD | 156 | 4.01 | 1.57 (1.34–1.83) | ||
ALD | 32 | 4.33 | 1.63 (1.15–2.30) | ||
Yes | No SLD | 393 | 7.74 | 1 (reference) | |
MASLD | 281 | 9.52 | 1.26 (1.08–1.46) | ||
MASLD with other combined etiology | 35 | 12.26 | 1.77 (1.25–2.50) | ||
MetALD | 1 | 7.92 | 1.61 (0.22–11.52) | ||
ALD | 1 | 27.42 | 8.05 (1.19–54.09) | ||
